U.S. energy firms seek exemption from Trump to transport LNG on U.S.-built ships. China Airlines orders Boeing passenger and ...

Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Vinay Prasad, an academic and fierce critic of the medical mainstream, has been chosen to be the next director of the FDA ...

Shares have slumped 60% since the Wall Street Journal reported in April that the company was preparing to file for bankruptcy ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...